LINKÖPING, Sweden, September 11, 2024 – AMRA Medical is excited to share that researchers working on impactful projects in the metabolic disease space will be sharing the findings from a recent abstract accepted for presentation at the European Association for the Study of Diabetes meeting, which runs to the 13th of September.
The study – based on 2,864 participants with Type 2 Diabetes (T2D) imaged within the UK Biobank study – investigated the associations of all-cause mortality with adverse muscle composition (AMC). AMC within the T2D population was common, as nearly 28% of participants possessed AMC. Furthermore, AMC was significantly associated with all-cause mortality within T2D, with a mortality risk over 3 times higher than those with T2D who exhibited normal muscle composition.
The findings come at a crucial point in time given the rapid growth in popularity of pharmacological interventions within T2D and other metabolic diseases, such as obesity. As these treatments become more effective in achieving larger weight reduction, the necessity for understanding the aspects of muscle health within the treatable patient population is growing, in order to ensure drug-induced weight-loss is safe and targeted.
Given the increased risk of death associated with AMC, it is paramount that muscle health is maintained and muscle composition should be monitored during pharmacological treatment for metabolic conditions such as T2D. The concern is greater for medicines that are intended to achieve large weight reductions, which could result in significant loss of muscle mass and induce sarcopenia, a condition associated with loss of strength and performance, and in turn, reduced quality of life. Including considerations of muscle health in emerging drug trials within the metabolic disease space will help prove safety and efficacy for new medications, and ultimately assist in getting new treatments to patients faster.
AMRA is proud to be leading the charge in muscle health monitoring within metabolic disease through the development of unique, informative body composition biomarkers that provide deeper-than-surface-level insights into an individual’s fat and muscle health. You can learn more about how we’re advancing metabolic disease research and beyond here, by finding us at EASD this week and reading our submitted abstract, or by reaching out to one of our knowledgeable scientists at info@amramedical.com.
View the recorded presentation here.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA’s gold-standard technology delivers multiple fat and muscle biomarkers – derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research.
MEDIA CONTACT INFORMATION
AMRA Medical
Marie Börjesson, VP Brand & Marketing
0046 70 628 1977
marie.borjesson@amramedical.com